Chimeric Antigen Receptor Therapy (CAR-T) is the latest breakthrough in oncology care. Simply put, it involves taking a patient’s cells, sending them to the drug manufacturer where they are re-engineered, and then infusing them back into the patient to attack the patient’s cancer. CAR-T will impact many core aspects of revenue integrity, including reimbursement.
Transitioning to an electronic health system comes with its challenges, from learning new software systems to updating staff roles. Understanding the resources your facility has available is critical to adapting to these changes.
With healthcare billing growing in complexity each year, healthcare organizations must take extra steps to maximize reimbursement and maintain compliance.
